InGel Therapeutics is Harvard-spinoff, regenerative cell-therapy biotech leveraging the novel neuro-protective and neuro-repairing mechanisms to tackle retinal degeneration. Our beachhead indication is Retinitis Pigmentosa, with future expansion opportunities include dry AMD and Glaucoma.